[Market Focus] Samchundang Pharm Rebounds Over 10% Amid Controversy View original image

After controversy arose over the possible overvaluation of a contract for generic (copycat) oral obesity and diabetes treatments, Samchundang Pharm shares, which had been plummeting for several days, rebounded in early trading on April 9.


As of 9:44 a.m. on this day, Samchundang Pharm shares were up 9.90% from the previous day, trading at 533,000 won. This slight rebound follows a series of steep declines since the company's shares hit a record high of 1,233,000 won during intraday trading on March 30. The previous day, Samchundang Pharm's stock price fell to 435,000 won, representing a 64.7% drop from its peak in just seven trading sessions.


Previously, in 2018, Samchundang Pharm signed a technology development agreement for Espas with Summit Biotech. According to the company, under the agreement, Samchundang Pharm was responsible for bearing all research and development expenses, including animal testing costs and researchers' salaries, in exchange for securing all legal rights, including patent ownership and commercialization rights. However, controversy erupted when it became known that Summit Biotech filed a patent application related to Espas in June 2024.



Additionally, negative sentiment was fueled by news that Summit Biotech CEO, Heo Jangsan, had previously been convicted of violating securities laws in Taiwan. Heo reportedly brokered the contract between Samchundang Pharm and a Taiwanese contract development and manufacturing organization (CDMO), and subsequently earned illegal profits from the deal.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing